PARP and cancer--if it's broke, don't fix it.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed.

1. Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma.Journal of experimental & clinical cancer research : CR · 2020
   Article
2. Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.International journal of molecular sciences · 2020
   Review
3. Expression of FAM83H and ZNF16 are associated with shorter survival of patients with gallbladder carcinoma.Diagnostic pathology · 2020
   Article
4. Annals of laboratory medicine · 2020
   Review
5. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.Journal of experimental & clinical cancer research : CR · 2018
   Article
6. SIRT6 Is Involved in the Progression of Ovarian Carcinomas via β-Catenin-Mediated Epithelial to Mesenchymal Transition.Frontiers in oncology · 2018
   Article
7. Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.Blood cancer journal · 2017
   Article
8. Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.PloS one · 2016
   Article
9. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo.PeerJ · 2016
   Article
10. Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.Translational oncology · 2015
    Article
11. PARP1-driven apoptosis in chronic lymphocytic leukemia.BioMed research international · 2014
    Article
12. PARP inhibitors: current status and implications for anticancer therapeutics.Infectious agents and cancer · 2013
    Article
13. Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Paediatric drugs · 2013
    Review
14. Treating breast cancer in the 21st century: emerging biological therapies.Journal of Cancer · 2013
    Article
15. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012
    Article
16. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.Cancer cell · 2011
    Article
17. Targeting the missing links for cancer therapy.Nature medicine · 2011
    Article
18. The ups and downs of tannins as inhibitors of poly(ADP-ribose)glycohydrolase.Molecules (Basel, Switzerland) · 2011
    Review
19. Management options in triple-negative breast cancer.Breast cancer : basic and clinical research · 2011
    Article
20. BRCA mutation testing in determining breast cancer therapy.Cancer journal (Sudbury, Mass.)
    Review

Corrections and comments

• Comment on
  Iniparib plus chemotherapy in metastatic triple-negative breast cancer.2011

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as